More Articles

ECCO position statement on biosimilars Biosimilars/General | Posted 27/06/2014

The European Crohn’s and Colitis Organisation (ECCO) is a non-profit association with the aim of improving the care of patients with inflammatory bowel disease (IBD) in Europe. The association curr...

Influence of CETA on generics Generics/Research | Posted 27/06/2014

On 18 October 2013, the European Union (EU) and Canada reached a political agreement on the key elements for a Comprehensive Economic and Trade Agreement (CETA). However, CETA has been criticized f...

Biologicals dominate Europe’s best sellers Reports | Posted 27/06/2014

The landscape of blockbuster medicines in Europe has been changing over the last years from small molecule drugs to biologicals.

EMA changes transparency plans to increase access to data Policies & Legislation | Posted 27/06/2014

The European Medicines Agency (EMA) has done an about-turn on its data transparency plans after the agency’s draft on the conditions of use for the EMA interface were criticized for limiting access...

Biosimilar infliximab comparable to Remicade Biosimilars/Research | Posted 27/06/2014

Results from a phase III trial have demonstrated the comparability of US-based Epirus Biopharmaceuticals (Epirus) biosimilar (BOW015) to Remicade for the treatment of rheumatoid arthritis.

Court rules Canadian drug regulators cannot control generics' prices Policies & Legislation | Posted 27/06/2014

Canada’s Patented Medicine Prices Review Board (PMPRB) has been told that it has no jurisdiction over the pricing of generics.

Pfenex looking for funding for its biosimilars pipeline Pharma News | Posted 27/06/2014

US biotechnology firm Pfenex is looking to raise more than US$45 million to further its biosimilars pipeline.

Can the pursuit of biosimilar interchangeability go too far? Biosimilars/Research | Posted 20/06/2014

The question of biosimilar interchangeability – whether or not a biosimilar can safely be switched with another biosimilar or with the originator product – is a thorny one. In fact, write Hans C Eb...